Neuroendocrine Tumor Therapy Response Assessment

Vetri Sudar Jayaprakasam; Lisa Bodei

doi:10.1016/j.cpet.2022.11.009

Neuroendocrine Tumor Therapy Response Assessment

PET Clin. 2023 Apr;18(2):267-286. doi: 10.1016/j.cpet.2022.11.009.

Authors

Vetri Sudar Jayaprakasam¹, Lisa Bodei²

Affiliations

¹ Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
² Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: bodeil@mskcc.org.

PMID: 36858748
DOI: 10.1016/j.cpet.2022.11.009

Abstract

Peptide receptor radionuclide therapy has become an integral part of management of neuroendocrine neoplasms. Gallium-68- and lutetium-177-labeled somatostatin receptor analogues have replaced yttrium-90- and 111-indium-based tracers. Several newer targeted therapies are also being used in clinical and research settings. It is imperative to accurately evaluate the response to these agents. The characteristics of NENs and the response patterns of the targeted therapies make response assessment in this group challenging. This article provides an overview of the strengths and weaknesses of the various biomarkers available for response assessment.

Keywords: DOTA-Tyr(3)-octreotate; NETest; Neuroendocrine neoplasms; PPQ; Peptide receptor radionucleotide therapies; Response.

Publication types

Review

MeSH terms

Humans
Neuroendocrine Tumors*
Somatostatin

Substances

Somatostatin